Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELEBRATE
jRCT2031230456Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of etoposide, carboplatin and durvalumab in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Overall survival. Started Jan 2024; status: recruiting.
02
Drugs
etoposidecarboplatindurvalumab
03
Conditions
gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on jRCT2031230456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230456.